Despite advances in pharmacologic and nonpharmacologic management, nausea and vomiting (N / V) remain serious adverse effects on cancer patients and their families. Dronabinol, a synthetic delta-9-THC, was approved in the United States in 1986 as an antiemetic to be used in the treatment of cancer.

Nabilone, a synthetic derivative

Of delta-9-THC, was first approved in Canada in 1982 and is now available in the United States. [35] Both dronabinol and nabilone are approved by the U.S. Food and Drug Administration (FDA) for the treatment of N / V associated with cancer chemotherapy in patients who have failed to respond to standard antiemetic treatment.

Numerous clinical trials and meta-analyzes have shown that dronabinol and nabilone are effective in treating N / V-induced chemotherapy. [36-39] The National Comprehensive Cancer Network Guidelines recommend cannabinoids as an.

• Effective
• Related
• Treatment
• Chemotherapy

The American Society

For Clinical Oncology (ASCO) reviewed antiemetic guidelines in 2017 recommends that FDA-approved cannabinoids, dronabinol or nabilone, be used to treat N / V resistant to standard antiemetic treatment .

One systematic review studied 30 randomized comparisons of delta-9-THC preparations with Cannabis edible or other antiemetics from which performance and injury data were obtained.

Oral nabilone, oral dronabinol, and intramuscular levonantradol (a synthetic analogue of dronabinol) were tested. Inhaled Cannabis trials are not included. Of all the 1,366 patients included in the review, cannabinoids were found to be more effective than the usual prochlorperazine antiemetics, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, and azoapride.

Cannabinoids

However, have not been very effective in patients receiving very low or very high emetogenic Weed edibles. Adverse effects included a feeling of height, excitement, anger or drowsiness, dizziness, dysphoria or depression, hallucinations, paranoia, and high blood pressure.

Another analysis of 15 controlled studies compared nabilone with placebo or available antiemetic drugs. Among the 600 cancer patients, nabilone has been found to be higher than prochlorperazine, domperidone, and akazapride, and nabilone is preferred for continuous use.

• The Cochrane meta-analysis of 23 RCTs reviewed studies
• Conducted between 1975 and 1991
• That investigated dronabinol or nabilone
• As monotherapy or as an adjunct to
• Normal dopamine antagonists who
• Were common antiemetics at the time

Chemical treatments involved low-, middle-, or high-dose drugs. Meta-analyzes rated the quality of Cannabis gummies as low for most outcomes. The review concluded that people are more likely to report total N / V deficiency when receiving cannabinoids compared to placebo, although they are more likely to withdraw from the study due to adverse events.

1. People reported higher
2. Selections of cannabinoids
3. Than placebo or
4. Prochlorperazine

There was no difference in the antiemetic effect of cannabinoids compared with Weed candy. The authors concluded that Cannabis-based medications may be useful in treating refractory chemotherapy-induced N / V; however, warn them that their testing may change with the availability of new antiemetic drugs.